Photo by jmuniz from unsplash
Dupilumab is a fully humanized Immunoglobulin-(Ig)-G4 antibody against the interleukin (IL)-4α subunit of the IL-4- and the IL-13-receptor.1 In patients with atopic eczema (AE), most frequent adverse reactions include injection… Click to show full abstract
Dupilumab is a fully humanized Immunoglobulin-(Ig)-G4 antibody against the interleukin (IL)-4α subunit of the IL-4- and the IL-13-receptor.1 In patients with atopic eczema (AE), most frequent adverse reactions include injection site reactions and conjunctivitis/blepharitis.1,2 Recently, a case with suspicion of an IgE-mediated hypersensitivity was reported.3 We herein report upon a patient who developed serum sickness like reaction (SSLR) under therapy with dupilumab.
Keywords:
like reaction;
serum sickness;
atopic eczema;
sickness like;
dupilumab
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!